The pharmaceutical industry is witnessing a paradigm shift as artificial intelligence (AI) transforms the landscape of drug development. Traditionally a lengthy and costly process, the creation of new medications is now being accelerated and streamlined through the application of AI technologies.
A recent whitepaper by the Learning Systems Platform highlights that AI implementation can significantly reduce the time from initial concept to drug approval. Currently, it takes an average of twelve years for a new drug to reach the market, with costs around $2.8 billion. AI-driven methods promise to substantially cut both time and expenses.
Concrete successes are already emerging. Biotech company Amgen has managed to shorten the development time for protein drug candidates to clinical trials by 60 percent. This was achieved through the use of AI-based computer models in combination with automated high-throughput laboratory procedures.
One promising area of application is the development of protein kinase inhibitors (PKIs). Scientists at the Lamarr Institute for Machine Learning and Artificial Intelligence are working with a database of approximately 156,000 PKIs, covering more than 80 percent of all human kinases. Using AI, they can identify and optimize potential drug candidates more rapidly.
AI is also showing great potential in oncology. An analysis of scientific publications revealed that AI applications are particularly frequent in cancer research. This could lead to faster progress in the development of new cancer drugs in the future.
The advantages of AI in drug development are manifold. They range from identifying new drug targets to better predictions of side effects and optimization of clinical trials. Experts predict that the full potential of AI in pharmaceutical research will unfold over the next 10 to 20 years.
Despite the promising outlook, challenges remain. These include building comprehensive, high-quality datasets and creating a legally secure regulatory framework for AI-based drug development. Nevertheless, experts agree: AI will significantly shape the future of pharmaceutical research and could pave the way for faster, more cost-effective, and potentially more effective medications.
The sources used in the article:
1. National Center for Biotechnology Information (NCBI) – PMC article on „The Role of AI in Drug Discovery: Challenges, Opportunities, and …“
2. National Center for Biotechnology Information (NCBI) – PMC article on „Artificial Intelligence in Pharmaceutical Technology and Drug …“
3. Harvard Law School Petrie-Flom Center blog – „How Artificial Intelligence is Revolutionizing Drug Discovery“
4. The Pharmaceutical Journal – „How AI is transforming drug discovery“
5. ScienceDirect – „Revolutionizing drug discovery: The impact of artificial intelligence …“
6. National Center for Biotechnology Information (NCBI) – PMC article on „Artificial intelligence in drug discovery and development“
7. Deutsches Ärzteblatt – „Arzneimittelentwicklung mit KI: Whitepaper zeigt Potenziale und Herausforderungen“
8. Digital Health Industry – „Künstliche Intelligenz entwickelt neue Medikamente“
These sources cover a range of perspectives on the use of AI in drug discovery and development, including academic research, industry insights, and regulatory considerations.
[1] The Role of AI in Drug Discovery: Challenges, Opportunities, and … https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302890/
[2] Artificial Intelligence in Pharmaceutical Technology and Drug … – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385763/
[3] How Artificial Intelligence is Revolutionizing Drug Discovery https://blog.petrieflom.law.harvard.edu/2023/03/20/how-artificial-intelligence-is-revolutionizing-drug-discovery/
[4] How AI is transforming drug discovery – The Pharmaceutical Journal https://pharmaceutical-journal.com/article/feature/how-ai-is-transforming-drug-discovery
[5] Revolutionizing drug discovery: The impact of artificial intelligence … https://www.sciencedirect.com/science/article/pii/S2949866X24000327
[6] Artificial intelligence in drug discovery and development – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/
[7] Arzneimittelentwicklung mit KI: Whitepaper zeigt Potenziale und Herausforderungen https://www.aerzteblatt.de/nachrichten/149777/Arzneimittelentwicklung-mit-KI-Whitepaper-zeigt-Potenziale-und-Herausforderungen
[8] Künstliche Intelligenz entwickelt neue Medikamente https://www.digital-health-industry.de/kuenstliche-intelligenz-revolutioniert-medikamenten-entwicklung-a-9599a6a95bc3fce8b1cf82911a0a7cae/
